Cardiac Biotech Solutions Inc. (CBSC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $5.96M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCardiac Biotech Solutions Inc. (CBSC) trades at $0.036. Cardiac Biotech Solutions Inc. focuses on ambulatory non-invasive cardiac monitoring. The company provides FDA and CE cleared EKG devices, cloud-based software, and smartphone apps. Market cap: $5.96M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CBSC: CBSC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBSC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CBSC: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Cardiac Biotech Solutions Inc. (CBSC) Healthcare & Pipeline Overview
Cardiac Biotech Solutions Inc. delivers ambulatory non-invasive cardiac monitoring solutions, including FDA and CE cleared EKG devices and interactive software. Operating in the medical instruments and supplies sector, the company aims to improve patient compliance and provide accurate data to physicians through its international subsidiaries and My-Cardia (USA), Inc.
What Is the Investment Thesis for CBSC?
Cardiac Biotech Solutions Inc. presents a focused investment opportunity within the ambulatory cardiac monitoring space. With FDA and CE cleared EKG devices, the company addresses a critical need for remote and continuous cardiac monitoring. Key value drivers include the potential for increased adoption of its cloud-based software and smartphone apps, which enhance patient compliance and data accuracy. The company's gross margin stands at 43.3%. Growth catalysts include expanding its market reach through international subsidiaries and strategic partnerships. Potential risks involve competition from established players and the need for continuous innovation to maintain a competitive edge. The company's small size (5 employees) and OTC market listing introduce additional volatility and liquidity concerns. The negative P/E ratio of -3.60 and profit margin of -1767.1% indicate current financial challenges that require careful monitoring.
Based on FMP financials and quantitative analysis
CBSC Key Highlights
FDA and CE cleared EKG devices provide a regulatory advantage in the ambulatory cardiac monitoring market.
- Gross margin of 43.3% indicates potential for profitability with increased sales volume.
- International subsidiaries enable market expansion and diversification of revenue streams.
- Cloud-based acquisition software and smartphone apps enhance patient compliance and data accessibility.
- My-Cardia (USA), Inc. subsidiary focuses on developing long-term ECG recording devices for ambulatory settings.
Who Are CBSC's Competitors?
CBSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CPIVF Captiva Verde Wellness Corp. | $0.06 | -20.55% | $17.7M | — |
| ENZN Enzon Pharmaceuticals, Inc. | $4.71 | +1.29% | $31.1M | — |
| IDXG Interpace Biosciences, Inc. | $6.51 | -6.73% | $36.1M | 519-signal |
| LUCY Innovative Eyewear, Inc. | $0.84 | -3.05% | $5.31M | — |
| FEMY Femasys Inc. | $2.74 | -3.18% | $8.27M | — |
| RGNT Regentis Biomaterials Ltd. | $1.89 | -3.57% | $13.3M | 645-pillar |
| ZJYL Jin Medical International Ltd. | $2.06 | -8.44% | $16.1M | 405-pillar |
| HBIO Harvard Bioscience, Inc. | $8.16 | +0.12% | $36.8M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CBSC's Key Strengths?
FDA and CE cleared EKG devices.
- Interactive cloud-based acquisition software.
- Smartphone apps for iOS and Android platforms.
- Wholly-owned U.S. subsidiary, My-Cardia (USA), Inc.
What Are CBSC's Weaknesses?
Small company size (5 employees).
- Negative P/E ratio and profit margin.
- OTC market listing with potential liquidity concerns.
- Limited brand recognition compared to larger competitors.
What Could Drive CBSC Stock Higher?
Potential partnerships with hospitals and clinics to expand market reach.
- Development and launch of advanced AI-powered diagnostic tools.
- Expansion into new geographic markets through international subsidiaries.
- Increasing adoption of remote patient monitoring solutions in geriatric care.
What Are the Key Risks for CBSC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the cardiac monitoring market.
- Regulatory changes and compliance requirements.
- Technological advancements that could render existing products obsolete.
- Limited financial disclosure and transparency due to OTC listing.
- Negative P/E ratio and profit margin indicating financial challenges.
What Are the Growth Opportunities for CBSC?
- Expanding market reach through strategic partnerships: Cardiac Biotech Solutions Inc. can leverage partnerships with hospitals, clinics, and telehealth providers to expand its market reach and increase adoption of its cardiac monitoring solutions. The global telehealth market is projected to reach $55.6 billion by 2027, presenting a significant opportunity for CBSC to integrate its technology into remote patient care platforms. Timeline: Ongoing.
- Developing advanced AI-powered diagnostic tools: Integrating artificial intelligence (AI) and machine learning (ML) algorithms into its cloud-based software can enhance the accuracy and efficiency of cardiac data analysis. CBSC can leverage AI to identify subtle patterns and anomalies in ECG data, providing physicians with valuable insights. Timeline: 1-2 years.
- Focusing on geriatric care and remote monitoring: The aging population and the increasing prevalence of chronic diseases are driving the demand for remote patient monitoring solutions, particularly in geriatric care. Cardiac Biotech Solutions Inc. can tailor its products and services to meet the specific needs of elderly patients, such as ease of use and remote data transmission. The geriatric care market is projected to reach $1.04 trillion by 2028. Timeline: Ongoing.
- Entering new geographic markets through international subsidiaries: Cardiac Biotech Solutions Inc. can leverage its international subsidiaries to expand its presence in emerging markets with high growth potential. These markets often have a greater need for affordable and accessible cardiac monitoring solutions. The Asia-Pacific medical device market is expected to grow at a CAGR of 8.8% from 2021 to 2028, presenting a significant opportunity for CBSC to establish a foothold in the region. Timeline: 2-3 years.
- Enhancing mobile app functionality and user experience: Improving the functionality and user experience of its iOS and Android apps can drive greater patient engagement and compliance. This includes features such as personalized reminders, educational content, and seamless data sharing with healthcare providers. The mobile health (mHealth) market is projected to reach $254 billion by 2026, driven by the increasing adoption of smartphones and the growing demand for remote healthcare services. Timeline: 6-12 months.
What Are CBSC's Competitive Advantages?
- FDA and CE clearances provide a regulatory barrier to entry.
- Proprietary cloud-based software and mobile apps offer a differentiated solution.
- Established international subsidiaries provide a global distribution network.
What Does CBSC Do?
Cardiac Biotech Solutions Inc. (CBSC) operates in the ambulatory non-invasive cardiac monitoring sector, providing products and services through its international subsidiaries. The company's core offerings include FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps compatible with both iOS and Android platforms. These solutions are designed to improve patient compliance for individuals at risk of abnormal heart rhythms and to provide physicians with more accurate diagnostic information. CBSC's wholly-owned U.S. subsidiary, My-Cardia (USA), Inc., is responsible for developing ECG recording devices that patients can wear in an ambulatory setting for up to 30 days. Cardiac Biotech Solutions Inc. focuses on innovation in the cardiac monitoring space, leveraging technology to enhance the accuracy and accessibility of diagnostic tools. The company's solutions cater to the growing need for remote patient monitoring and aim to streamline the process of cardiac data acquisition and analysis. With a focus on ambulatory settings, CBSC's products are designed to provide continuous monitoring without requiring patients to be confined to a hospital or clinic. The company's international presence allows it to serve a diverse range of markets and adapt its offerings to meet specific regional requirements. By combining hardware, software, and mobile applications, Cardiac Biotech Solutions Inc. seeks to offer a comprehensive solution for cardiac monitoring and diagnostics.
What Products and Services Does CBSC Offer?
- Develops and markets ambulatory non-invasive cardiac monitoring devices.
- Offers FDA and CE cleared EKG devices for accurate heart rhythm monitoring.
- Provides interactive cloud-based software for data acquisition and analysis.
- Creates smartphone apps for iOS and Android platforms to enhance patient compliance.
- Develops ECG recording devices worn by patients for up to 30 days.
- Offers solutions for remote patient monitoring in ambulatory settings.
- Focuses on improving the accuracy and accessibility of cardiac diagnostic tools.
How Does CBSC Make Money?
- Sells EKG devices and related hardware to healthcare providers and patients.
- Offers subscription-based access to its cloud-based software platform.
- Generates revenue through international subsidiaries in various markets.
What Industry Does CBSC Operate In?
Cardiac Biotech Solutions Inc. operates within the medical instruments and supplies industry, which is experiencing growth due to the increasing prevalence of cardiovascular diseases and the demand for remote patient monitoring solutions. The market is competitive, with established players like CPIVF (CardioComm Solutions Inc.) and emerging companies vying for market share. Trends include the integration of AI and machine learning for improved diagnostics and the development of wearable devices for continuous monitoring. Cardiac Biotech Solutions Inc. aims to differentiate itself through its integrated hardware, software, and mobile app solutions.
Who Are CBSC's Key Customers?
- Hospitals and clinics that require cardiac monitoring solutions.
- Physicians who need accurate data for diagnosing heart rhythm abnormalities.
- Patients at risk of abnormal heart rhythms who need remote monitoring.
- Telehealth providers seeking to integrate cardiac monitoring into their services.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 48 |
| 2026-08-26 | 48 |
| 2026-08-29 | 48 |
| 2026-09-01 | 48 |
| 2026-09-04 | 48 |
| 2026-09-07 | 48 |
| 2026-09-10 | 48 |
What changed?
The score has stayed at 48.
Over the same 18 days the stock moved -5.3%.
Cardiac Biotech Solutions Inc. (CBSC) Valuation Context
Valued at $5.96M, CBSC is classified as a micro-cap stock.
CBSC Revenue & Earnings Trend
In Q1 FY2026, CBSC generated $40K in top-line revenue, marking a sequential decrease of 0.8%. The company recorded a net loss of $137K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CBSC averaged $-0.00 in diluted EPS.
Company Profile
Cardiac Biotech Solutions Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Charles K. Martin. CBSC has traded publicly since 2016.
Key Financial Metrics
Return on equity for Cardiac Biotech Solutions Inc. stands at 58.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -23.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -24.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Cardiac Biotech Solutions Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CBSC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- FDA and CE cleared EKG devices.
- Interactive cloud-based acquisition software.
- Smartphone apps for iOS and Android platforms.
- Wholly-owned U.S. subsidiary, My-Cardia (USA), Inc.
Bear Case
- Small company size (5 employees).
- Negative P/E ratio and profit margin.
- OTC market listing with potential liquidity concerns.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2026 | $40,154 | -$137,173 | -$0.0008 |
| Q4 FY2025 | $40,460 | -$103,048 | -$0.0006 |
| Q3 FY2025 | $40,329 | -$573,681 | -$0.0035 |
| Q2 FY2025 | $26,868 | -$40,505 | -$0.0002 |
Q1 FY2026 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
CBSC Latest News
No recent news available for CBSC.
CBSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CBSC.
Price Targets
Wall Street price target analysis for CBSC.
CBSC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CBSC; grades run from A+ (80-100) to F (below 30).
Leadership: Charles K. Martin
CEO
Charles K. Martin is the CEO of Cardiac Biotech Solutions Inc., leading a team of 5 employees. His background includes experience in managing and growing small businesses, with a focus on healthcare technology. He has a proven track record of driving innovation and expanding market reach. Martin's expertise lies in identifying emerging trends and developing solutions that address unmet needs in the cardiac monitoring space. His leadership is focused on building a strong team and fostering a culture of innovation and customer focus.
Track Record: Under Charles K. Martin's leadership, Cardiac Biotech Solutions Inc. has achieved FDA and CE clearance for its EKG devices and launched its cloud-based software and smartphone apps. He has overseen the expansion of the company's international subsidiaries and the development of the My-Cardia (USA), Inc. subsidiary. Martin has also focused on building strategic partnerships to expand the company's market reach and increase adoption of its solutions.
CBSC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cardiac Biotech Solutions Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries a higher degree of risk due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies may not be required to file regular financial reports with the SEC, making it difficult for investors to assess their financial health and performance.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher volatility and lower liquidity compared to exchange-listed stocks.
- Lack of regulatory oversight and investor protection.
- Going concern risk due to negative P/E ratio and profit margin.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's competitive position and market share.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory filings.
- Check for any history of fraud or misconduct.
- Understand the risks associated with investing in OTC stocks.
- FDA and CE clearances for EKG devices.
- Development of cloud-based software and smartphone apps.
- Establishment of international subsidiaries.
- Focus on innovation in the cardiac monitoring space.
What Investors Ask About Cardiac Biotech Solutions Inc. (CBSC) — Healthcare
Is CBSC a good stock?
Stock Expert AI does not rate CBSC buy, sell or hold. Cardiac Biotech Solutions Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CBSC stock?
As of 2026-03-18, there is no available analyst coverage for Cardiac Biotech Solutions Inc. due to its OTC listing and small market capitalization.
What are the key factors to evaluate for CBSC?
Evaluate CBSC on fundamentals, analyst consensus, and risk factors. With FDA and CE cleared EKG devices, the company addresses a critical need for remote and continuous cardiac monitoring. Not financial advice.
How frequently does CBSC data refresh on this page?
CBSC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CBSC's recent stock price performance?
Cardiac Biotech Solutions Inc. (CBSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: FDA and CE cleared EKG devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBSC overvalued or undervalued right now?
Cardiac Biotech Solutions Inc. (CBSC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CBSC?
Yes, most major brokerages offer fractional shares of Cardiac Biotech Solutions Inc. (CBSC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBSC's earnings and financial reports?
Cardiac Biotech Solutions Inc. (CBSC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CBSC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.